Friday, January 29, 2021

Ayala Pharmaceuticals (AYLA)
First Patient Dose in Breast Cancer Trial

Ayala Pharmaceuticals Inc clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The company’s current portfolio of product candidates, AL101 and AL102, targets the aberrant activation of the Notch pathway with gamma secretase inhibitors. Its product candidate, AL101, is being developed as a potent, selective, injectable small molecule gamma secretase inhibitor, or GSI. It is also developing AL101 for the treatment of T-ALL, an aggressive, rare form of T-cell specific leukemia.

Ahu Demir, Ph. D., Biotechnology Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

TNBC trial is active. Yesterday, Ayala Pharmaceuticals announced that the first patient was dosed in its Phase 2 TENACITY clinical trial of its potent, selective small molecule AL101 for the treatment of patients with Notch-activated recurrent or metastatic (R/M) triple negative breast cancer (TNBC).


TENACITY details.  The open-label, multicenter, single arm Phase 2 study will evaluate the efficacy and safety of AL101 monotherapy in patients with Notch-activated R/M TNBC. It is expected to initially enroll up to 26 patients with Notch-activated R/M TNBC whose disease has recurred or progressed after three or fewer lines of prior therapy. Notch activation will be determined using a Next …

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision.